Actinium Pharmaceuticals to Showcase ATNM-400's First-in-Human Clinical Data in Prostate Cancer and Preclinical Results in Lung Cancer Supporting Pan-Tumor Potential Today at EANM 2026
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
| Actinium Pharmaceuticals, Inc. (NYSE: ATNM) | Delayed: 1.38 -0.02 (1.43%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.40 | 52 Week High | $3.50 | |||
| Open | $1.38 | 52 Week Low | $0.86 | |||
| Day High | $1.41 | P/E | N/A | |||
| Day Low | $1.33 | EPS | $-7.61 | |||
| Volume | 358,228 | |||||
